Home CBD Study with 10mg CBD: can reduce severe anxiety and symptoms

Study with 10mg CBD: can reduce severe anxiety and symptoms

through druginc

Study with 10mg CBD: can reduce severe anxiety and symptoms

According to a presentation at the annual conference of the Anxiety and Depression Association of America taking a sublingual cannabidiol product may reduce severe anxiety and anxiety-related symptoms.

“This is the first-ever study to look at a whole plant and CBD as a full spectrum product in patients with moderate to severe anxiety,” said Staci Gruber, PhD, director of Marijuana Investigations for Neuroscientific Discovery at McLean Hospital.

So far, the researchers have completed the open-label phase of the study. They were designed to determine the correct dose of the product, evaluate clinical assessments of anxiety, mood, sleep and quality of life, assess cognitive performance by multiple measures, and examine the safety profile for serious adverse events. 4 patients received 14 mg / ml for 10 weeks CBD.

The results showed that the study drug was well tolerated, with patients reporting no serious side effects or intoxication. Patients used about 3,5 ml of CBD per day. Overall analyzes showed significantly improved anxiety ratings according to the Beck Anxiety Inventory (79,94% decrease), the Overall Anxiety and Disorders Scale (70,24% decrease), and the Hamilton Anxiety Rating Scale (82,98% decrease). Furthermore, the results showed a 77,93% decrease on the Beck Depression Inventory and 63,67% on the profile of mood states: total mood disorders. Gruber and colleagues also saw significant improvements in sleep and quality of life assessments. Furthermore, patients showed stable or improved measures of executive function over time.

A total of seven patients (50%) tested positive for THC metabolites after 4 weeks.

Further studies for the use of CBD against anxiety

Further studies for the use of CBD against anxiety
Further studies for the use of CBD against anxiety (afb.)

“A final assessment of the impact of this product will be established in the double-blind, placebo-controlled phase, which is currently underway,” said Gruber. "Larger sample studies are needed to more thoroughly assess which variables (product use, BMI, age, gender, race, drug use, etc.) contribute to positive THC status in some individuals."

Sources include Harvard (EN), healio (EN), Science Direct (EN)

Related Articles

Comments